HEPATITIS C

REPORTING INFORMATION

- **Class B2:** Report by the end of the business week after the case or suspected case, and/or a positive laboratory result to the local public health department where the patient resides. If patient residence is unknown, report to the local public health department in which the reporting health care provider or laboratory is located.
- Reporting Form(s) and/or Mechanism: Viral Hepatitis Case Report form, Ohio Confidential Reportable Disease form (HEA 3334, rev. 1/09), Positive Laboratory Findings for Reportable Disease form (HEA 3333, rev. 8/05), the local health department via the Ohio Disease Reporting System (ODRS), or telephone.
- Information collected from the Viral Hepatitis Case Report form, Ohio Confidential Reportable Disease form (HEA 3334, rev. 1/09), or Positive Laboratory Findings for Reportable Disease form (HEA 3333, rev. 8/05) should be entered into ODRS and not mailed to the Ohio Department of Health (ODH), unless otherwise requested.
- Additional reporting information, with specifics regarding the key fields for ODRS Reporting can be located in Section 7.

AGENT

Hepatitis C virus is classified in the Flaviviridae family, and is the only member of the Hepacivirus genus. Hepatitis C virus is a single-stranded RNA virus, 40-50nm in diameter. At least six different genotypes and more than 50 subtypes of hepatitis C virus exist.

TEST NAME ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgM anti-HAV</td>
<td>Immunoglobulin M antibody to hepatitis A virus</td>
</tr>
<tr>
<td>HBsAg</td>
<td>Hepatitis B surface antigen</td>
</tr>
<tr>
<td>IgM anti-HBc</td>
<td>Immunoglobulin M antibody to hepatitis B core antigen</td>
</tr>
<tr>
<td>Anti-HCV</td>
<td>Antibody to hepatitis C virus</td>
</tr>
<tr>
<td>HCV RNA</td>
<td>Hepatitis C virus RNA</td>
</tr>
<tr>
<td>NAT</td>
<td>Nucleic acid test</td>
</tr>
<tr>
<td>RIBA</td>
<td>Recombinant immunoblot assay</td>
</tr>
<tr>
<td>s/co</td>
<td>Signal to cut-off ratio</td>
</tr>
<tr>
<td>ALT (SGPT)</td>
<td>Serum alanine aminotransferase</td>
</tr>
<tr>
<td>AST (SGOT)</td>
<td>Serum aspartate aminotransferase</td>
</tr>
<tr>
<td>EIA</td>
<td>Enzyme immunoassay</td>
</tr>
</tbody>
</table>

CASE DEFINITION

**Hepatitis C, Acute**

**Clinical Case Definition**

An acute illness with a discrete onset of any sign or symptom consistent with acute viral hepatitis (such as nausea, vomiting, abdominal pain and anorexia) and either a) jaundice/dark urine or b) abnormal serum aminotransferase levels (ALT levels greater than 400 IU/L).

**Laboratory Criteria for Diagnosis**

- IgM anti-HAV negative, **AND**
- IgM anti-HBc negative, **AND** one or more of the following:
  - anti-HCV screening-test-positive verified by an additional more specific assay (e.g. RIBA or HCV RNA) or
- anti-HCV screening-test-positive with a signal to cut-off ratio predictive of a true positive as determined for the particular assay as defined by CDC. (URL for the signal to cut-off ratios: http://www.cdc.gov/ncidod/diseases/hepatitis/c/sc_ratios.htm).
- Hepatitis C Virus Recombinant Immunoblot Assay (HCV RIBA) positive, OR
- Nucleic Acid Test (NAT) for HCV RNA positive (including genotype)

**Case Classification**

**Suspect:** A case that is reported by a health-care professional as acute hepatitis C without laboratory results.

**Probable:** A case that does not meet the clinical case definition, but has supportive serologic findings of hepatitis C infection, and is a clinically compatible case, as reported by a health-care professional.

**Confirmed:** A case that meets the clinical case definition, is laboratory confirmed, and is not known to have chronic hepatitis C.

**Hepatitis C, Past or Present**

**Clinical Description**

No symptoms are required. Most HCV-infected persons are asymptomatic; however, many have chronic liver disease, which can range from mild to severe.

**Laboratory Criteria for Diagnosis**

- Anti-HCV positive (repeatedly reactive) by EIA, verified by at least one additional more specific assay or
- HCV RIBA positive or
- Nucleic Acid Test (NAT) positive for HCV RNA (including genotype), OR
- Anti-HCV positive by EIA with a signal to cut-off ratio predictive of a true positive as determined for the particular assay and posted by CDC. (http://www.cdc.gov/ncidod/diseases/hepatitis/c/sc_ratios.htm).

**Case Classification**

**Suspect:** A case that is reported by a health-care professional as chronic hepatitis C without laboratory results; or anti-HCV positive test by EIA that has not been verified by an additional and more specific assay, and the signal to cut-off ratios are unknown.

**Probable:** A case that is reported by a health-care professional as chronic hepatitis C with supportive serologic findings of hepatitis C infection (ODH); or a case that is anti-HCV positive (repeatedly reactive) by EIA and has ALT or SGPT values above the upper limit of normal, but the anti-HCV EIA result has not been verified by an additional more specific assay or the signal to cut-off ratio is unknown (CDC).

**Confirmed:** A case that is laboratory confirmed and does not meet the case definition for acute hepatitis C.

**Comments**

1) Up to 20% of acute hepatitis C cases will be anti-HCV negative when reported and will be classified as acute viral hepatitis C with undetermined etiology because some (5% - 10%) have not yet seroconverted and others (5% - 10%) remain negative even with prolonged follow-up.
2) Available serologic tests for anti-HCV do not distinguish between acute and chronic or past infection. Thus, other causes of acute hepatitis should be excluded for anti-HCV positive patients who have an acute illness compatible with viral hepatitis.

**SIGNS AND SYMPTOMS**
Acute infection is usually asymptomatic. Symptomatic infection is generally mild, with malaise being the most common manifestation. Fulminant disease is rare. After acute infection, approximately 15% - 45% of persons resolve their infection without sequelae as defined by sustained absence of HCV RNA in serum and normalization of ALT levels. Chronic hepatitis C virus infection develops in 55% - 85% of those infected. Active liver disease develops in 60% - 70% of chronically infected persons and is accompanied by persistent or fluctuating ALT levels; the progression of disease is usually slow and without symptoms or physical signs during the first two or more decades after infection. Cirrhosis develops in 5% - 20% of the chronically infected over a period of 20-30 years, and hepatocellular carcinoma in 1% - 5%.

**DIAGNOSIS**
Past or present hepatitis C is diagnosed first by an anti-HCV screening test; two examples are enzyme immunoassay (EIA) and enhanced chemiluminescence immunoassay (CIA). Positive anti-HCV results are then confirmed with a more specific assay (e.g. recombinant immunoblot assay [RIBA] or NAT for HCV RNA) or confirmed by a signal to cut-off ratio (s/co) predictive of a true positive as defined by CDC (URL for the signal to cut-off ratios: http://www.cdc.gov/ncidod/diseases/hepatitis/c/sc_ratios.htm). An anti-HCV-positive person is defined as one whose serologic results are screening-test-positive and supplemental-test-positive. Persons with a negative anti-HCV or a positive anti-HCV and a negative supplemental test result are considered uninfected, unless other evidence exists to indicate hepatitis C infection. Indeterminate supplemental test results have been observed in: recently infected persons who are in the process of seroconversion; persons chronically infected with hepatitis C; and persons with a false positive result, especially those at low risk for hepatitis C infection. The presence of current hepatitis C infection can be ascertained, either qualitatively or quantitatively, by detecting HCV RNA using gene amplification techniques (e.g. reverse transcriptase polymerase chain reaction [RT-PCR]). A negative HCV RNA indicates that viremia is absent, but it does not confirm a false positive EIA or that a patient has resolved their infection.

The table below summarizes interpretation of laboratory findings:

<table>
<thead>
<tr>
<th>Laboratory Findings</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-HCV screening</td>
<td>Anti-HCV supplemental test</td>
</tr>
<tr>
<td>Negative</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Positive with high s/co ratio</td>
<td>Not done</td>
</tr>
<tr>
<td>Positive</td>
<td>RIBA positive</td>
</tr>
<tr>
<td>Positive</td>
<td>RIBA negative</td>
</tr>
<tr>
<td>Positive</td>
<td>RIBA indeterminate</td>
</tr>
</tbody>
</table>

ODH - IDC M  HEPATITIS C Page 3/Section 3  Revised 7/2011
<table>
<thead>
<tr>
<th>Positive HCV RNA positive</th>
<th>Indicates active hepatitis C infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive HCV RNA negative Riba positive</td>
<td>The presence of anti-HCV indicates past or present hepatitis C infection; a single negative HCV RNA result does not rule out active infection</td>
</tr>
<tr>
<td>Positive HCV RNA negative Riba negative</td>
<td>Does not indicate hepatitis C infection</td>
</tr>
<tr>
<td>Positive HCV RNA negative Riba indeterminate</td>
<td>Anti-HCV screening probably a false-positive; does not indicate hepatitis C infection</td>
</tr>
</tbody>
</table>

*Samples with high s/co ratios usually (95%) confirm positive, but <5 of every 100 might represent false positives; more specific testing can be requested, if indicated.*

**Epidemiology**

**Source**
Hepatitis C virus is found in human blood and blood products.

**Occurrence**
Hepatitis C infection is prevalent throughout the world. Hepatitis C is the most common chronic bloodborne infection in the United States. Since 2003, acute, symptomatic hepatitis C hepatitis rates have plateaued within all age groups. In 2008, rates increased slightly among persons aged 15-24 years (0.4 cases per 100,000 population) and were highest for persons aged 25-39 years (0.5 cases per 100,000 population). Few cases were reported among persons aged < 15 years. Historically, rates of acute, symptomatic hepatitis C have been higher among males than females. Since 2002, the male-to-female ratio of rates has declined. In 2008, incidence among males and females was 0.3 cases per 100,000 population, yielding a ratio of 1. In 2008, acute, symptomatic hepatitis C rates were highest among American Indian/Alaskan Natives (0.5 cases per 100,000 population) and lowest among Asian/Pacific Islanders (0.04 cases per 100,000 population) compared to the other racial/ethnic groups.

Although the annual number of new infections has declined since 1989 by more than 90% to an estimated 18,000 in 2008, there are an estimated 4.1 million persons (1.6% of the non-institutionalized population) who have been infected with hepatitis C and about 3.2 million (1.3% of the non-institutionalized population) who are chronically infected. The peak prevalence is in persons 50-59 years of age, the majority of whom were likely infected during the 1970s and 1980s when rates for hepatitis C were the highest. Those who are chronically infected serve as a source of transmission to others and are at risk for chronic liver disease or other hepatitis C-related chronic diseases.

**Mode of Transmission**
Currently, hepatitis C is rarely transmitted by blood transfusion (less than one chance per two million units transfused) or organ transplantation; however, prior to donor screening, both blood transfusion and organ transplantation carried a high risk for transmission of hepatitis C. Injecting drug use, through transfer of infected blood by sharing needles or other drug paraphernalia, is currently the predominant mode of hepatitis C transmission in the United States. Nosocomial transmission of hepatitis C is possible if infection-control techniques or disinfection procedures are inadequate and contaminated equipment is shared among patients. Health-care, emergency medical and public safety workers who are exposed to blood in the workplace are at risk of being infected with bloodborne pathogens, including hepatitis C. Sexual transmission of hepatitis C appears to occur, but the virus is inefficiently spread in this manner.
Hepatitis C transmission to nonsexual household contacts, presumably through direct or inapparent percutaneous or permucosal exposure to infectious blood or body fluids containing blood, is uncommon. There is a 5%-6% risk that hepatitis C may also be transmitted perinatally from HCV RNA-positive pregnant women to their infants. If a woman is co-infected with HIV, this risk increases to approximately 14%.

**Period of Communicability**
Communicability lasts from one or more weeks before onset of first symptoms through the acute clinical course of the disease and indefinitely in the chronic carrier stages.

**“At-Risk” Groups**
Groups at high risk of acquiring this infection are injection drug users who share needles or other drug paraphernalia; prison inmates; heterosexuals with multiple partners; hemodialysis patients; medical, dental and laboratory workers with exposure to blood; and household or other close contacts of known cases.

**Incubation Period**
The incubation period ranges from 2 weeks to 6 months with an average of 6-9 weeks.

**PUBLIC HEALTH MANAGEMENT**

**Case Investigation**
Determine through the patient’s physician if the patient is/was acutely ill and meets the case definition (see above).

**Treatment**
No therapeutic measures have been proven effective for acute hepatitis C following the onset of disease. It has been suggested that treatment should be considered in most instances after 2-4 months of waiting for spontaneous clearance, but more data is needed. Doctors usually recommend rest, adequate nutrition, and fluids. Persons with acute or chronic liver disease due to viral hepatitis or other causes are advised to avoid drinking alcohol and eating raw shellfish, such as oysters.

Antiviral therapy is recommended for patients with chronic hepatitis C who are at greatest risk for progression to cirrhosis. These persons include anti-HCV-positive patients with persistently elevated serum alanine aminotransferase (ALT) levels, detectable HCV RNA and a liver biopsy that indicates either portal or bridging fibrosis or at least moderate degrees of inflammation and necrosis. Currently, treatment consists of a combination of pegylated interferon injected once a week along with ribavirin in pill form taken twice daily. Interferon monotherapy is generally reserved for patients in whom ribavirin is contraindicated. Two protease inhibitors (Boceprevir and Telaprevir) were approved by the FDA in May 2011 for hepatitis C genotype 1. Protease inhibitors work by blocking the replication of the hepatitis C virus. These protease inhibitors are in pill form and are taken every 7-9 hours with food. Because of advances in the field of antiviral therapy for chronic hepatitis C, with resultant changes in the standards of practice, the most up-to-date information may be obtained through consultation with specialists knowledgeable in this area.

**Isolation**
None, beyond the universal application of blood and body fluid precautions. Persons diagnosed with hepatitis C should not donate blood.
Prevention and Control
General control measures against hepatitis B virus infection apply for hepatitis C virus infection as well (see hepatitis B elsewhere in this manual). The value of prophylactic immunoglobulin (IG), however, is not clear. Current data suggest that postexposure prophylaxis with IG is not effective in preventing hepatitis C infection. No assessments have been made of postexposure use of antiviral agents (e.g., interferon) to prevent hepatitis C infection. Mechanisms of the effect of interferon in treating patients with hepatitis C are poorly understood, and an established infection might need to be present for interferon to be an effective treatment. Interferon is currently FDA-approved only for treatment of chronic hepatitis C. There is no vaccine available.

Special Information
Personnel from the Bureau of HIV/AIDS, STD and TB at the ODH are available to answer questions regarding hepatitis C. Please call 614-644-1838.

Many excellent fact sheets and other resources are available at the CDC Web site: http://www.cdc.gov/hepatitis.
What is hepatitis C?
Hepatitis C is a liver disease caused by the hepatitis C virus, which is found in the blood of persons who have this disease. Hepatitis C is spread by contact with the blood of an infected person.

How is hepatitis C diagnosed?
There are several blood tests that can be done to determine if you have been infected with hepatitis C. Your doctor may order just one or a combination of these tests. The following are the types of tests your doctor may order and the purpose for each:

- Anti-HCV (antibody to hepatitis C)
  - EIA (enzyme immunoassay).
    - This test is usually done first. If positive, it should be confirmed.
  - RIBA (recombinant immunoblot assay).
    - A supplemental test used to confirm a positive EIA test.

Anti-HCV does not tell whether the infection is new (acute), chronic (long-term) or is no longer present (resolved). If you have a confirmed positive anti-HCV, your doctor can order a test for HCV RNA which will tell you if you have the virus present in your blood which indicates that you are currently infected.

Who should get tested for hepatitis C?
- current or former injection drug users, including those who injected only once or a few times many years ago
- persons who were treated for clotting problems with a blood product made before 1987 when more advanced methods for manufacturing the products were developed
- persons who were notified that they received blood or an organ from a donor who later tested positive for hepatitis C
- persons who received a blood transfusion or solid organ transplant before July 1992 when better testing of blood donors became available
- long-term hemodialysis patients
- persons who have signs or symptoms of liver disease (e.g., abnormal liver enzyme tests)
- healthcare workers after exposures (e.g., needle sticks or splashes to the eye) to hepatitis C-positive blood on the job
- children born to hepatitis C-positive women
- persons who received body piercing or tattoos done with non-sterile instruments
- persons with HIV infection

How is hepatitis C virus spread from one person to another?
Hepatitis C virus is spread primarily by direct contact with human blood. For example, you may have gotten infected with hepatitis C virus if:
- you ever injected street drugs (even once), because the needles and/or other drug “works” used to prepare or inject the drug(s) may have had someone else's blood that contained hepatitis C virus on them
- you received blood, blood products, or solid organs from a donor whose blood contained hepatitis C virus
- you were ever on long-term kidney dialysis as you may have unknowingly shared supplies/equipment that had someone else's blood on them
- you were ever a healthcare worker and had frequent contact with blood on the job,
especially accidental needle sticks
• your mother had hepatitis C at the time she gave birth to you; during birth her blood may have gotten into your body
• you ever had sex with a person infected with hepatitis C virus
• you lived with someone who was infected with hepatitis C virus and shared items such as razors or toothbrushes that might have had his/her blood on them

Is there any evidence that hepatitis C virus has been spread during medical or dental procedures done in the United States?
Medical and dental procedures done in most settings in the United States do not pose a risk for the spread of hepatitis C. There have, however, been some reports that hepatitis C virus has been spread between patients in hemodialysis units where supplies or equipment may have been shared between patients and in outpatient clinics where proper infection control was not maintained.

Can hepatitis C virus be spread by sexual activity?
Yes, but this does not occur very often. If you are having sex, but not with one steady partner:
• you and your partners can get other diseases spread by having sex (e.g. HIV, hepatitis B, syphilis, gonorrhea or chlamydia)
• you should use latex condoms correctly and every time you have sex
• you should get vaccinated against hepatitis B

Can hepatitis C virus be spread within a household?
Yes, but this does not occur very often. If hepatitis C virus is spread within a household, it is most likely due to direct exposure to the blood of an infected household member.

Should pregnant women be routinely tested for anti-HCV?
No. Pregnant women have no greater risk of being infected with hepatitis C virus than non-pregnant women, and interventions to prevent mother-to-child transmission are lacking. If pregnant women have risk factors for hepatitis C, they should be tested for anti-HCV.

What is the risk that hepatitis C virus-infected women will spread hepatitis C virus to their newborn infants?
Approximately 4 out of every 100 infants born to hepatitis C virus-infected women become infected; however, the risk becomes greater if the mother has both HIV infection and hepatitis C. Infection occurs at the time of birth, and there is no treatment that can prevent this from happening. Most infants infected with hepatitis C virus at the time of birth have no symptoms and do well during childhood. More studies are needed to find out if these children will have problems from the infection as they grow older. There are no licensed treatments or guidelines for the treatment of infants or children under the age of three years infected with hepatitis C virus. Children with elevated ALT (liver enzyme) levels should be referred for evaluation to a specialist familiar with the management of children with hepatitis C virus-related disease.

Should a woman with hepatitis C be advised against breast-feeding?
No. There is no evidence that breast-feeding spreads hepatitis C virus. Hepatitis C virus-positive mothers should consider abstaining from breast-feeding if their nipples are cracked or bleeding.
How can you protect yourself from getting hepatitis C and other diseases spread by contact with human blood?
- Do not ever shoot drugs. If you shoot drugs, stop and get into a treatment program. If you cannot stop, never reuse or share syringes, water or drug works, and get vaccinated against hepatitis A and hepatitis B.
- Do not share toothbrushes, razors or other personal care articles. They might have blood on them.
- If you are a healthcare worker, always follow standard precautions and safely handle needles and other sharps. Get vaccinated against hepatitis B.
- Consider the health risks if you are thinking about getting a tattoo or body piercing. You can get infected if:
  - the tools that are used have someone else's blood on them.
  - the artist or piercer doesn't follow good health practices, such as washing hands and using disposable gloves.
  - the ink used for your tattoo is contaminated with someone else's blood.

What can persons with hepatitis C virus infection do to protect their livers?
- Stop using alcohol.
- See the doctor regularly.
- Do not start any new medicines or use over-the-counter, herbal and other medicines or supplements without a physician's knowledge.
- Get vaccinated against hepatitis A and hepatitis B.

What other information should patients with hepatitis C be aware of?
- Hepatitis C virus is not spread by sneezing, hugging, coughing, food or water, sharing eating utensils or drinking glasses, or casual contact.
- Persons should not be excluded from work, school, play, child-care or other settings on the basis of their hepatitis C virus infection status. There is no evidence of hepatitis C transmission from food handlers, teachers, or other service providers in the absence of blood-to-blood contact. There is a low but present risk for transmission with sex partners.
- Sharing personal items that might have blood on them, such as toothbrushes or razors, can pose a risk to others.
- Cuts and sores on the skin should be covered to keep from spreading infectious blood or secretions.
- Donating blood, organs, tissue, or semen can spread hepatitis C to others.
- Involvement with a support group may help patients cope with hepatitis C.

What are the chances of persons with hepatitis C virus infection developing long term infection, chronic liver disease, cirrhosis, liver cancer, or dying as a result of hepatitis C?
Of every 100 persons infected with HCV approximately:
- 75-85 persons will develop long-term infection,
- 60-70 persons will develop chronic liver disease,
- 5-20 persons will develop cirrhosis over a period of 20 to 30 years, and
- 1-5 persons will die from the consequences of long term infection (liver cancer or cirrhosis).

What is the treatment for chronic hepatitis C?
Antiviral drugs such as interferon used alone or in combination with ribavirin, are approved for the treatment of persons with chronic hepatitis C. Interferon works in 10-20 persons out
Interferon combined with ribavirin works in up to 50 out of 100 persons with genotype 1, the most common genotype found in the U.S. and up to 80 out of 100 persons with genotypes 2 or 3. Ribavirin, when used alone, does not work. Two new drugs were approved in May 2011 to treat persons with hepatitis C genotype 1. These drugs are protease inhibitors that work by stopping the hepatitis C virus from making more copies of itself. They are taken in pill form with food every 7-9 hours and are taken in addition to interferon and ribavirin combination therapy. This new triple therapy works in up to approximately 80 out of 100 persons with genotype 1.
This page intentionally left blank.
**Disease Fact Sheet**

**Hepatitis C and Healthcare Workers**

**What is the risk for hepatitis C virus infection from a needle stick exposure to hepatitis C virus contaminated blood?**
After needle stick or sharps exposure to hepatitis C virus-positive blood, about 2 healthcare workers out of 100 (1.8%) will get infected with hepatitis C virus (range 0% - 10%).

**Other than needlesticks, do other other exposures, such as splashes to the eye, pose a risk to healthcare personnel for HCV transmission?**
Although a few cases of hepatitis C transmission via blood splash to the eye have been reported, the risk for such transmission is expected to be very low. Avoiding occupational exposure to blood through the use of Standard Precautions is the primary way to prevent transmission of bloodborne infections among health care personnel. Depending on the medical procedure involved, Standard Precautions may include the appropriate use of personal protective equipment such as gloves, masks, gowns, and protective eyewear.

**What are the recommendations for follow-up of healthcare workers after exposure to hepatitis C virus-positive blood?**
Anti-viral agents (e.g. interferon) or immune globulin should not be used for postexposure prophylaxis.
1. For the source, baseline testing for anti-HCV.
2. For the person exposed to a hepatitis C virus-positive source, baseline and follow-up testing including:
   - baseline testing for anti-HCV and ALT activity; and
   - follow-up testing for anti-HCV and ALT activity at 4-6 months. (If earlier diagnosis of hepatitis C virus infection is desired, testing for HCV RNA may be performed at 4-6 weeks.)
3. Confirmation by supplemental anti-HCV testing of all anti-HCV results reported as positive by enzyme immunoassay.

**Should hepatitis C virus-infected healthcare workers be restricted in their work?**
No. There are no recommendations to restrict a healthcare worker who is infected with hepatitis C virus. The risk of transmission from an infected healthcare worker to a patient appears to be very low. As recommended for all healthcare workers, those who are hepatitis C virus-positive should follow strict aseptic technique and Standard Precautions, including appropriate use of hand washing, protective barriers and care in the use and disposal of needles and other sharp instruments. Hepatitis C virus-infected healthcare workers who perform exposure-prone procedures should refer to the Ohio Department of Health Updated Recommendations for HIV, HCV, and HBV Infected Healthcare Workers, 2006 which can be found at www.odh.ohio.gov/alerts/alerts.aspx.